{
  "id": 9132544,
  "title": "HighLife Raises $90 Million To Start US Heart Valve Study and Grow in Europe",
  "url": "https://urgent.news/2026/09/22/highlife-raises-90-million-to-start-us-heart-valve-study-and-grow-in",
  "topic": "business",
  "section": "Business",
  "published": "2026-09-22T11:19:26.000Z",
  "source": {
    "name": "Ventureburn",
    "slug": "ventureburn",
    "url": "https://ventureburn.com/highlife-raises-90-million-us-study-europe-expansion/"
  },
  "original_language": "en",
  "account": "HighLife, a biotech company focused on structural heart disease, has secured $90 million in new funding. The capital will be used to expand its market presence in Europe and advance its clinical program in the United States. HighLife's key product, the Transcatheter Mitral Valve Replacement (TMVR) system, aims to address mitral regurgitation, a condition where the mitral valve fails to close properly, causing blood to leak backward. The company has received CE Mark approval for both its initial TMVR system and its next-generation valve, the Clarity Valve. However, selling its products in the US requires successful completion of a pivotal study, which is costly and time-consuming. The funding round, led by Andera Partners, Sofinnova Partners, Supernova Invest, and Mérieux Equity Partners, also attracted participation from several European investment firms and strategic investors. With this new capital, HighLife intends to strengthen its manufacturing capabilities, enhance regulatory compliance, and expand its US clinical trial network.",
  "summary": "There are four valves in the heart that ensure blood flows correctly. The mitral valve is between the left chambers of the heart. When it is not properly closed up, The post HighLife Raises $90 Million To Start US Heart Valve Study and Grow in Europe appeared first on Ventureburn .",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}